Key result
Platelet glycoprotein IIb/IIIa inhibitors reduce thrombotic events and mortality in acute coronary syndromes, supporting their routine use in critical pathways despite cost constraints.
Answers are grounded in this paper and cite their sources.
The benefits of GP IIb/IIIa receptor inhibition in reducing thrombotic events and mortality suggest the utility of adopting their routine use in critical pathways for unstable angina/NSTEMI and PCI, potentially targeted based on patient risk assessment due to cost constraints.
Platelet glycoprotein (GP) IIb/IIIa inhibitors have been shown to be effective in reducing thrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) and when used as medical therapy in patients with unstable angina/non-ST-segment elevation myocardial infarction (MI). Recent findings include dramatic preventive benefits in the setting of coronary stent deployment and a significant long-term preventive effect on mortality. The benefits of GP IIb/IIIa receptor inhibition suggest the utility of adopting routine use of these agents in critical pathways of unstable angina/non-ST-segment elevation MI and PCI. Because cost constraints may limit use of these agents, however, targeting treatment based on patient risk assessment may be warranted.
No takes yet. Share an insight, caveat, or question.
Christopher P. Cannon (1999) conducted a review in Unstable angina/non-ST-segment elevation myocardial infarction. Platelet glycoprotein (GP) IIb/IIIa inhibitors was evaluated. Platelet glycoprotein IIb/IIIa inhibitors reduce thrombotic events and mortality in acute coronary syndromes, supporting their routine use in critical pathways despite cost constraints.
Synapse has enriched 10 related papers. Consider them for comparative context: